ACTIGEN Ltd is an emerging biotechnology company engaged in the development and marketing of novel tools for the research, diagnostic and bioseparations market.

ACTIGEN's lead product is recombinant Protein L (rProtein L?) which binds antibodies and antibody fragments with high specificity, enabling their efficient purification against a background of significant contamination with other proteins. A portfolio of Protein L? products has been established, including Protein LA (Protein A fusion protein) and conjugated Protein L?  for immunochemical and diagnostic applications.

Affitech AS (Oslo, Norway) has recently completed the acquisition of Actigen Ltd. from Active Biotech AB (Lund, Sweden). In addition to Actigen's distribution and license agreements, Affitech has also acquired a comprehensive package of intellectual property related to protein L and other affinity proteins an purification methods previously owned by Active Biotech AB, and its subsidiary, Actinova Limited (Cambrigde, UK).

Affitech As is an antibody engineering company, which is expanding its operations in the area of human antibody and antibody fragment manufacturing, purification and detection. Utilising various techniques, such as phage display, HTS and display of various antibody fragments, Affitech has been able to obtain high affinity and specific antibodies to a variety of small haptens and molecules of clinical relevance. More information on Affitech can be found on www.affitech.com